The Stock Connect Innovative Drug ETF E Fund (159316) attracted over 2.2 billion in the past three months

I'm LongbridgeAI, I can summarize articles.

As of 14:08, the Hang Seng Stock Connect Innovative Drug Index (HSSCID) fell by 1.94%; among the top ten weighted stocks, Innovent Biologics dropped 1.5%, BeiGene dropped 2.27%, CSPC Pharmaceutical Group dropped 1.98%, Akeso dropped 2.24%, China National Pharmaceutical Group dropped 2.09%, Hansoh Pharmaceutical dropped 3.23%, Sinopharm Group dropped 1.61%, Kelun-Biotech dropped 2.89%, Zai Lab dropped 0.35%, and Conba Biopharma rose 1.64%.

The Stock Connect Innovative Drug ETF E Fund (159316) continues to attract capital inflows. As of the previous trading day, net inflows totaled 1.798 billion yuan over the past month, 2.22 billion yuan over the past three months, and 6.86 billion yuan over the past year.

The overseas expansion of domestic innovative drugs is accelerating. According to data from Kyong Securities, cross-border licensing deals (License Out) in China's biopharmaceutical sector significantly accelerated in July, with 12 deals concluded in a single month, totaling $9.253 billion.

Additionally, according to Arterial Intelligence, the number of BD transactions for innovative drugs in China in the first half of 2026 has already reached 71% of the total for all of 2025, approximately 240 deals; the total transaction value reached $106.3 billion, about 80% of the full-year 2025 figure.

A research report from Guojin Securities points out that domestic innovative drugs have undergone investment and financing accumulation and technological iteration. Their pipeline reserves in cutting-edge sub-sectors such as ADCs (Antibody-Drug Conjugates), bispecific antibodies, and small nucleic acids are globally leading. Coupled with the high barriers created by China's innovative drug industry's triple advantages in regulatory review, clinical efficiency, and development costs, Chinese innovative drug companies are deeply embedded in the global pharmaceutical industry chain.

The management fee rate for the Stock Connect Innovative Drug ETF E Fund (159316) is 0.15%, the custody fee rate is 0.05%, and the comprehensive fee rate is 0.2%. The relatively low fees can effectively reduce cost expenditures for investors.

The Stock Connect Innovative Drug ETF E Fund (159316) is currently the only ETF product tracking the Hang Seng Innovative Drug Index on the market, possessing high elasticity and scarcity, helping investors better seize this round of investment opportunities in Hong Kong stock innovative drugs.